Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-312025-12-310true116truefalsetrueNo description of principal activity2025-01-01false101false 05395143 2025-01-01 2025-12-31 05395143 2024-01-01 2024-12-31 05395143 2025-12-31 05395143 2024-12-31 05395143 1 2025-01-01 2025-12-31 05395143 1 2024-01-01 2024-12-31 05395143 4 2025-01-01 2025-12-31 05395143 4 2024-01-01 2024-12-31 05395143 1 2025-01-01 2025-12-31 05395143 d:Exceptional 2025-01-01 2025-12-31 05395143 d:Exceptional 2024-01-01 2024-12-31 05395143 e:Director1 2025-01-01 2025-12-31 05395143 e:Director2 2025-01-01 2025-12-31 05395143 e:Director2 2025-12-31 05395143 e:Director3 2025-01-01 2025-12-31 05395143 e:Director4 2025-01-01 2025-12-31 05395143 e:Director5 2025-01-01 2025-12-31 05395143 e:Director5 2025-12-31 05395143 e:Director6 2025-01-01 2025-12-31 05395143 e:Director6 2025-12-31 05395143 e:RegisteredOffice 2025-01-01 2025-12-31 05395143 d:Buildings d:LongLeaseholdAssets 2025-01-01 2025-12-31 05395143 d:Buildings d:LongLeaseholdAssets 2025-12-31 05395143 d:Buildings d:LongLeaseholdAssets 2024-12-31 05395143 d:PlantMachinery 2025-01-01 2025-12-31 05395143 d:PlantMachinery 2025-12-31 05395143 d:PlantMachinery 2024-12-31 05395143 d:PlantMachinery d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 05395143 d:OfficeEquipment 2025-01-01 2025-12-31 05395143 d:OfficeEquipment 2025-12-31 05395143 d:OfficeEquipment 2024-12-31 05395143 d:OfficeEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 05395143 d:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 05395143 d:OtherPropertyPlantEquipment 2025-12-31 05395143 d:OtherPropertyPlantEquipment 2024-12-31 05395143 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 05395143 d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 05395143 d:PatentsTrademarksLicencesConcessionsSimilar 2025-01-01 2025-12-31 05395143 d:PatentsTrademarksLicencesConcessionsSimilar 2025-12-31 05395143 d:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 05395143 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-01-01 2025-12-31 05395143 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-12-31 05395143 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-12-31 05395143 d:Goodwill 2025-01-01 2025-12-31 05395143 d:NegativeGoodwill 2025-01-01 2025-12-31 05395143 d:NegativeGoodwill 2025-12-31 05395143 d:NegativeGoodwill 2024-12-31 05395143 d:ComputerSoftware 2025-01-01 2025-12-31 05395143 d:ComputerSoftware 2025-12-31 05395143 d:ComputerSoftware 2024-12-31 05395143 d:OtherResidualIntangibleAssets 2025-01-01 2025-12-31 05395143 d:CurrentFinancialInstruments 2025-12-31 05395143 d:CurrentFinancialInstruments 2024-12-31 05395143 d:Non-currentFinancialInstruments 2025-12-31 05395143 d:Non-currentFinancialInstruments 2024-12-31 05395143 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 05395143 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 05395143 d:Non-currentFinancialInstruments d:AfterOneYear 2025-12-31 05395143 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 05395143 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-12-31 05395143 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-12-31 05395143 f:UnitedKingdom 2025-01-01 2025-12-31 05395143 f:UnitedKingdom 2024-01-01 2024-12-31 05395143 f:RestWorldOutsideUK 2025-01-01 2025-12-31 05395143 f:RestWorldOutsideUK 2024-01-01 2024-12-31 05395143 d:UKTax 2025-01-01 2025-12-31 05395143 d:UKTax 2024-01-01 2024-12-31 05395143 d:ShareCapital 2025-12-31 05395143 d:ShareCapital 2024-12-31 05395143 d:SharePremium 2025-01-01 2025-12-31 05395143 d:SharePremium 2025-12-31 05395143 d:SharePremium 2024-12-31 05395143 d:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 05395143 d:RetainedEarningsAccumulatedLosses 2025-12-31 05395143 d:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 05395143 d:RetainedEarningsAccumulatedLosses 2024-12-31 05395143 d:RetainedEarningsAccumulatedLosses 2024-01-01 05395143 d:AcceleratedTaxDepreciationDeferredTax 2025-12-31 05395143 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 05395143 d:TaxLossesCarry-forwardsDeferredTax 2025-12-31 05395143 d:TaxLossesCarry-forwardsDeferredTax 2024-12-31 05395143 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2025-01-01 2025-12-31 05395143 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2025-12-31 05395143 d:FurtherSpecificTypeProvisionContingentLiability1ComponentTotalProvisionsContingentLiabilities 2024-12-31 05395143 e:OrdinaryShareClass1 2025-01-01 2025-12-31 05395143 e:OrdinaryShareClass1 2025-12-31 05395143 e:OrdinaryShareClass1 2024-12-31 05395143 e:FRS102 2025-01-01 2025-12-31 05395143 e:Audited 2025-01-01 2025-12-31 05395143 e:FullAccounts 2025-01-01 2025-12-31 05395143 e:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 05395143 d:WithinOneYear 2025-12-31 05395143 d:WithinOneYear 2024-12-31 05395143 d:BetweenOneFiveYears 2025-12-31 05395143 d:BetweenOneFiveYears 2024-12-31 05395143 d:PatentsTrademarksLicencesConcessionsSimilar d:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 05395143 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 05395143 d:NegativeGoodwill d:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 05395143 d:ComputerSoftware d:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 05395143 2 2025-01-01 2025-12-31 05395143 4 2025-01-01 2025-12-31 05395143 5 2025-01-01 2025-12-31 05395143 d:ExternallyAcquiredIntangibleAssets 2025-01-01 2025-12-31 05395143 d:NegativeGoodwill d:OwnedIntangibleAssets 2025-01-01 2025-12-31 05395143 d:PatentsTrademarksLicencesConcessionsSimilar d:OwnedIntangibleAssets 2025-01-01 2025-12-31 05395143 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:OwnedIntangibleAssets 2025-01-01 2025-12-31 05395143 d:ComputerSoftware d:OwnedIntangibleAssets 2025-01-01 2025-12-31 05395143 g:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 05395143










SYMPROVE LTD










ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

 
SYMPROVE LTD
 
 
COMPANY INFORMATION


Directors
M J Butler 
B E Smith (resigned 22 January 2026)
A D Gibbs 
W P J Bowler 
P E Konney (appointed 22 January 2026)
P Smallcombe (appointed 22 January 2026)




Registered number
05395143



Registered office
Sandy Farm
The Sands

Farnham

Surrey

GU10 1PX




Independent auditor
Shaw Gibbs (Audit) Limited
Statutory Auditor

Wey Court West

Union Road

Farnham

Surrey

GU9 7PT





 
SYMPROVE LTD
 

CONTENTS



Page
Strategic report
 
1 - 2
Directors' report
 
3 - 4
Independent auditor's report
 
5 - 8
Statement of income and retained earnings
 
9
Statement of financial position
 
10 - 11
Notes to the financial statements
 
12 - 30


 
SYMPROVE LTD
 
 
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

Introduction
 
The company’s principal activity is the manufacture and sale of a water-based food supplement containing four strains of live and active bacteria to support the gut microbiome.

Business review
 
The results of the company for the financial year, as set out on page 9, show a profit on ordinary activities before tax of £2,024,752 (2024: profit of £2,826,587). The net assets of the company total of £4,726,949 (2024: net assets of £3,877,558).

Principal risks and uncertainties
 
The following are considered the principal risks and uncertainties for the company:
Regulatory
A major incident in food safety could negatively impact customers’ trust in Symprove and could cause reputational damage to the brand. The company maintains the highest standards of food safety through the internal processes in place to monitor and enhance food hygiene and safety standards, a robust product testing regime and only sourcing high quality ingredients. These processes are assessed and validated as part of the company’s BRC Start! accreditation.
Financial
The company’s operations expose it to a variety of financial risks that include the effects of credit risk and foreign exchange risk. The company specifically manages these risks to minimise their impact on financial performance.
• Credit risk
As a D2C business the majority of the company’s sales are pre-authorised on debit/credit cards where credit risk is low. However, the company does have a number of retail customers which expose it to credit risk. The company closely monitors its outstanding debts and has implemented policies that require appropriate credit checks on potentially significant new customers before any sales are made. Customer credit limits are reviewed and updated periodically, and monthly ageing reviews are carried out and appropriate follow-up action is taken.
• Currency risk
The company works with a distributor for sales in the Republic of Ireland who purchase in Euros, which means that the company is exposed to currency risks. Exposure is limited as the company undertakes periodic spot transactions to convert currency balances into GBP to minimize currency risk.
 

Financial key performance indicators
 
The company monitors revenue growth, operating profit and cash flow monthly as its key financial performance measures.

Other key performance indicators
 
Non-financial measures such as key customer metrics are also monitored by the company. 

Page 1

 
SYMPROVE LTD
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025


This report was approved by the board and signed on its behalf.







A D Gibbs
Director

Date: 15 September 2026

Page 2

 
SYMPROVE LTD
 
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025

The directors present their report and the financial statements for the year ended 31 December 2025.

Directors' responsibilities statement

The directors are responsible for preparing the Strategic report, the Directors' report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgments and accounting estimates that are reasonable and prudent;

∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Results and dividends

The profit for the year, after taxation, amounted to £849,391 (2024 - £2,504,527).

A dividend has not been declared (2024 : £Nil).

Directors

The directors who served during the year were:

M J Butler 
B E Smith (resigned 22 January 2026)
A D Gibbs 
W P J Bowler 

Future developments

The company continues to pursue growth in the UK and in internationally, with preparations currently underway to launch in new markets during 2027.

Research and development activities

The company is committed to scientific research and testing to support the effectiveness of its products. Several scientific studies have been carried out focusing on the effectiveness of the products unique delivery system, gut function and how this is impacted by use of multi-strain live bacteria products.

Page 3

 
SYMPROVE LTD
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025

Disclosure of information to auditor

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:
 
∙so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and

∙the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

Auditor
The auditor, Shaw Gibbs (Audit) Limited, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006. 

Post balance sheet events

On the 22nd January 2026, 100% of the parent company’s issued share capital was acquired by Metagenics UK Ltd.

This report was approved by the board and signed on its behalf.
 







A D Gibbs
Director

Date: 15 September 2026

Page 4

 
SYMPROVE LTD
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYMPROVE LTD
 

Opinion


We have audited the financial statements of Symprove Ltd (the 'Company') for the year ended 31 December 2025, which comprise the Statement of income and retained earnings, the Statement of financial position and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).


In our opinion the financial statements:


∙give a true and fair view of the state of the Company's affairs as at 31 December 2025 and of its profit for the year then ended;
∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
∙have been prepared in accordance with the requirements of the Companies Act 2006.


Basis for opinion


We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.


Conclusions relating to going concern


In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.


Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.


Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.


Page 5

 
SYMPROVE LTD
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYMPROVE LTD (CONTINUED)


Other information


The other information comprises the information included in the Annual Report other than the financial statements and our Auditor's report thereon. The directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.


We have nothing to report in this regard.


Opinion on other matters prescribed by the Companies Act 2006
 

In our opinion, based on the work undertaken in the course of the audit:


∙the information given in the Strategic report and the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Strategic report and the Directors' report have been prepared in accordance with applicable legal requirements.


Matters on which we are required to report by exception
 

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic report or the Directors' report.


We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:


∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
∙the financial statements are not in agreement with the accounting records and returns; or
∙certain disclosures of directors' remuneration specified by law are not made; or
∙we have not received all the information and explanations we require for our audit.


Responsibilities of directors
 

As explained more fully in the Directors' responsibilities statement set out on page 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.


In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.


Page 6

 
SYMPROVE LTD
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYMPROVE LTD (CONTINUED)


Auditor's responsibilities for the audit of the financial statements
 

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.


Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, and considered the risk of acts by the company that were contrary to applicable laws and regulations, including fraud. We designed audit procedures to respond to the risk, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
We focused on laws and regulations which could give rise to a material misstatement in the financial statements, including, but not limited to, the Companies Act 2006 and UK tax legislation. 
Our tests included agreeing the financial statement disclosures to underlying supporting documentation, enquiries with management. There are inherent limitations in the audit procedures described above and, the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. We did not identify any key audit matters relating to irregularities, including fraud. As in all our audits, we also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.
 
Page 7

 
SYMPROVE LTD
 
 
 
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SYMPROVE LTD (CONTINUED)




A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.


Use of our report
 

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.







Charlotte Anderson (Senior statutory auditor)
for and on behalf of
Shaw Gibbs (Audit) Limited
Statutory Auditor
Wey Court West
Union Road
Farnham
Surrey
GU9 7PT

15 September 2026
Page 8

 
SYMPROVE LTD
 
 
STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 DECEMBER 2025

2025
2024
Note
£
£

  

Turnover
 4 
36,864,604
27,728,822

Cost of sales
  
(10,500,618)
(7,455,783)

Gross profit
  
26,363,986
20,273,039

Administrative expenses
  
(20,158,065)
(17,658,745)

Exceptional administrative expenses
 13 
(4,263,136)
-

Other operating income
  
125,866
254,804

Operating profit
 6 
2,068,651
2,869,098

Interest receivable and similar income
 10 
692,015
600,000

Interest payable and similar expenses
 11 
(735,914)
(642,511)

Profit before tax
  
2,024,752
2,826,587

Tax on profit
 12 
(1,175,361)
(322,060)

Profit after tax
  
849,391
2,504,527

  

  

Retained earnings at the beginning of the year
  
3,752,358
1,247,831

Profit for the year
  
849,391
2,504,527

Retained earnings at the end of the year
  
4,601,749
3,752,358

There were no recognised gains and losses for 2025 or 2024 other than those included in the statement of income and retained earnings.

The notes on pages 12 to 30 form part of these financial statements.

Page 9

 
SYMPROVE LTD
REGISTERED NUMBER: 05395143

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Intangible assets
 14 
1,866,459
1,516,618

Tangible assets
 15 
4,516,690
3,475,707

  
6,383,149
4,992,325

Current assets
  

Stocks
 16 
1,330,578
633,062

Debtors: amounts falling due after more than one year
 17 
6,345,059
5,000,000

Debtors: amounts falling due within one year
 17 
5,985,093
4,801,921

Cash at bank and in hand
 18 
3,999,940
1,333,917

  
17,660,670
11,768,900

Creditors: amounts falling due within one year
 19 
(16,613,869)
(6,547,759)

Net current assets
  
 
 
1,046,801
 
 
5,221,141

Total assets less current liabilities
  
7,429,950
10,213,466

Creditors: amounts falling due after more than one year
 20 
(2,052,694)
(5,916,393)

Provisions for liabilities
  

Deferred tax
 22 
(547,239)
(419,515)

Other provision
 23 
(103,068)
-

  
 
 
(650,307)
 
 
(419,515)

Net assets
  
4,726,949
3,877,558


Capital and reserves
  

Called up share capital 
 24 
229
229

Share premium account
 25 
124,971
124,971

Profit and loss account
 25 
4,601,749
3,752,358

  
4,726,949
3,877,558


Page 10

 
SYMPROVE LTD
REGISTERED NUMBER: 05395143
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2025

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 






A D Gibbs
Director

Date: 15 September 2026

The notes on pages 12 to 30 form part of these financial statements.

Page 11

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Symprove Ltd (registered number 05395143) is a private company limited by shares and incorporated in England & Wales. The registered office is Sandy Farm, The Sands, Farnham, Surrey, GU10 1PX.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The accounts are presented in Sterling and rounded to the nearest £.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
∙the requirements of Section 7 Statement of Cash Flows;
∙the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
∙the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of BD-C Feeling Midco Limited as at 31 December 2025 and these financial statements may be obtained from Companies House, Crown Way, Cardiff, CF14 3UZ.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.



Page 12

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
∙the Company has transferred the significant risks and rewards of ownership to the buyer;
∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
∙the amount of revenue can be measured reliably;
∙it is probable that the Company will receive the consideration due under the transaction; and
∙the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.5

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.6

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.7

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.8

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.9

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 13

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.10

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.11

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.12

Exceptional items

Exceptional items are disclosed separately where it is necessary to do so to provide further understanding of the financial performance of the company. They are items that are material either because of their size or nature, or that are non-recurring and outside the scope of ordinary activities of the business. 

Page 14

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.13

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Development costs which are directly attributable to a product are recognised as intangible assets when the following criteria are met:
 
∙it is technically feasible to complete an intangible asset which will be available for use;
∙management intends to complete the intangible asset and use or sell it;
∙there is an ability to use or sell the intangible asset;
∙it can be demonstrated that the intangible asset will generate probable future economic benefits;
∙adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available; and
∙the expenditure attributable to the intangible asset during its development can be reliably
measured.

Other development expenses that do not meet these criteria are recognised in the profit and loss as
an expense in the period. Development costs previously expensed are not recognised as an asset in a subsequent period.

 The estimated useful lives range as follows:

Patents
-
10
years
Development expenditure
-
10
years
Software
-
5
years
Assets under construction
-
amortised once complete

 
2.14

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 15

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)


2.14
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight line and reducing balance methods.

Depreciation is provided on the following basis:

Property improvements
-
10% straight line
Plant and machinery
-
10% straight line
Office equipment
-
25% straight line
Assets under construction
-
depreciated once complete

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.15

Impairment of fixed assets

An assessment is made at each reporting date of whether there are indications that a fixed asset may be impaired or that an impairment loss previously recognised has fully or partially reversed. If such indications exist, the company estimates the recoverable amount of the asset.
Shortfalls between the carrying value of fixed assets and their recoverable amounts, being the higher of fair value less costs to sell and value-in-use, are recognised as impairment losses. Impairment losses are recognised in profit or loss.   
For fixed assets, recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Reversals of impairment losses are recognised in profit or loss. On reversal of an impairment loss, the depreciation or amortisation is adjusted to allocate the asset’s revised carrying amount (less any residual value) over its remaining useful life.

 
2.16

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

Page 16

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.17

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

A provision for impairment of trade debtors is established when there is objective evidence that the amounts due will not be collected according to the original terms of the contract. Impairment losses are recognised in profit or loss for the excess of the carrying value of the trade debtor over the present value of the future cash flows discounted using the original effective interest rate. Subsequent reversals of an impairment loss that objectively relate to an event occurring after the impairment loss was recognised, are recognised immediately in profit or loss. 

 
2.18

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.19

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

  
2.20

Provisions for liabilities

Provisions are recognised when the Company has an obligation at the reporting date as a result of a past event which it is probable will result in the transfer of economic benefits and that obligation can be estimated reliably.
Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar expenses.

 
2.21

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of
Page 17

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)


2.21
Financial instruments (continued)

financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Judgments in applying accounting policies and key sources of estimation uncertainty

The company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical judgment in applying the company’s accounting policies:

Capitalisation of development costs
Assessing whether the company’s research and development expenditure meets the criteria to be capitalised as intangible assets (as set out in note 2.13) requires judgment. The directors consider the outcome of R&D activities and assess the degree of certainty attached to the flow of future economic benefits that are attributable to the use of the asset on. 

Key sources of estimation uncertainty:
In the opinion of the directors there are currently no critical accounting estimates.
 
Page 18

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


Turnover

All turnover arose from the sale of goods from the company's principal activity.

Analysis of turnover by country of destination:

2025
2024
£
£

United Kingdom
30,803,230
22,502,633

Rest of the world
6,061,374
5,226,189

36,864,604
27,728,822



5.


Other operating income

2025
2024
£
£

Research and development tax credit
120,991
254,804

Sundry income
4,875
-

125,866
254,804



6.


Operating profit

The operating profit is stated after charging:

2025
2024
£
£

Research & development charged as an expense
226,665
231,758

Exchange differences
(31,125)
52,808

Depreciation
426,652
177,906

Amortisation
446,077
397,077

Operating leases
623,579
618,620

Exceptional items
4,263,136
-

Page 19

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

7.


Auditor remuneration

During the year, the Company obtained the following services from the Company's auditor:


2025
2024
£
£

Fees payable to the Company's auditor for the audit of the Company's financial statements
27,810
27,000

The Company has taken advantage of the exemption not to disclose amounts paid for non-audit services as these are disclosed in the consolidated accounts of the parent Company.


8.


Employees

Staff costs, including directors' remuneration, were as follows:


2025
2024
£
£



Wages and salaries
7,365,731
5,950,653

Social security costs
733,584
493,439

Cost of defined contribution scheme
212,677
157,215

8,311,992
6,601,307

The average monthly number of employees, including the directors, during the year was as follows:


2025
2024
No.
No.



Directors
4
4

Production
25
22

Administrative
87
75

116
101

Page 20

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

9.


Directors' remuneration

2025
2024
£
£

Directors' emoluments
943,661
593,691

Company contributions to defined contribution pension schemes
19,712
10,283

963,373
603,974


During the year retirement benefits were accruing to 2 directors (2024 - 2) in respect of defined contribution pension schemes.

The highest paid director received remuneration, including benefits, of £436,424 (2024 - £280,886).

The value of the Company's contributions paid to a defined contribution pension scheme in respect of the highest paid director amounted to £11,022 (2024 - £6,695).


10.


Interest receivable

2025
2024
£
£


Other interest receivable
692,015
600,000


11.


Interest payable and similar expenses

2025
2024
£
£


Other loan interest payable
689,895
642,511

Other interest payable
46,019
-

735,914
642,511

Page 21

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

12.


Taxation


2025
2024
£
£

Corporation tax


Current tax on profits for the year
961,446
142,106

Adjustments in respect of previous periods
86,191
26,507


1,047,637
168,613


Total current tax
1,047,637
168,613

Deferred tax


Movement in the year
127,724
153,447

Total deferred tax
127,724
153,447


Tax on profit
1,175,361
322,060
Page 22

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
 
12.Taxation (continued)


Factors affecting tax charge for the year

The tax assessed for the year is higher than (2024 - lower than) the standard rate of corporation tax in the UK of 25% (2024 - 25%). The differences are explained below:

2025
2024
£
£


Profit on ordinary activities before tax
2,024,752
2,826,587


Profit on ordinary activities multiplied by standard rate of corporation tax in the UK of 25% (2024 - 25%)
506,188
706,647

Effects of:


Expenses not deductible for tax purposes
1,036,737
(4,070)

Capital allowances for year in excess of depreciation
(123,736)
(189,054)

Utilisation of tax losses
-
(233,748)

Adjustments to tax charge in respect of prior periods
86,191
-

Other differences leading to an increase in taxation
36,236
83,453

Adjustment in research and development tax credit leading to an increase in the tax charge
-
(20,778)

Changes in provisions leading to an increase (decrease) in the tax charge
(6,916)
16,784

Group relief
(473,983)
(176,335)

Transfer pricing adjustments
(13,080)
(14,286)

Deferred tax movement
127,724
153,447

Total tax charge for the year
1,175,361
322,060


Factors that may affect future tax charges

There were no factors that may affect future tax charges.


13.


Exceptional items

2025
2024
£
£


Professional advisory and transaction support fees
4,263,136
-

Exceptional items comprise professional advisory and transaction support fees incurred during the year, relating to the post-balance sheet acquisition (note 30). The fees have been presented as exceptional due to their size and non-recurring nature and to provide a clearer understanding of the underlying trading performance of the company.

Page 23

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

14.


Intangible assets




Patents
Development expenditure
Software
Assets under construction
Total

£
£
£
£
£



Cost


At 1 January 2025
406,878
1,840,416
1,225,995
96
3,473,385


Additions
86,528
195,667
498,890
14,833
795,918


Transfers
-
-
96
(96)
-



At 31 December 2025

493,406
2,036,083
1,724,981
14,833
4,269,303



Amortisation


At 1 January 2025
213,658
1,101,414
641,695
-
1,956,767


Charge for the year on owned assets
35,568
142,556
267,953
-
446,077



At 31 December 2025

249,226
1,243,970
909,648
-
2,402,844



Net book value



At 31 December 2025
244,180
792,113
815,333
14,833
1,866,459



At 31 December 2024
193,220
739,002
584,300
96
1,516,618



Page 24

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

15.


Tangible fixed assets





Property improvements
Plant and machinery
Office equipment
Assets under construction
Total

£
£
£
£
£



Cost


At 1 January 2025
461,724
1,518,593
330,479
2,130,107
4,440,903


Additions
994,354
184,659
80,561
208,061
1,467,635


Transfers between classes
1,859,587
260,917
9,603
(2,130,107)
-



At 31 December 2025

3,315,665
1,964,169
420,643
208,061
5,908,538



Depreciation


At 1 January 2025
108,487
624,420
232,289
-
965,196


Charge for the year on owned assets
223,696
151,971
50,985
-
426,652



At 31 December 2025

332,183
776,391
283,274
-
1,391,848



Net book value



At 31 December 2025
2,983,482
1,187,778
137,369
208,061
4,516,690



At 31 December 2024
353,237
894,173
98,190
2,130,107
3,475,707


16.


Stocks

2025
2024
£
£

Raw materials and consumables
786,458
462,657

Work in progress (goods to be sold)
57,644
38,748

Finished goods and goods for resale
486,476
131,657

1,330,578
633,062


Page 25

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

17.


Debtors

2025
2024
£
£

Due after more than one year

Amounts owed by group undertakings
6,345,059
5,000,000


2025
2024
£
£

Due within one year

Trade debtors
1,675,461
742,768

Amounts owed by group undertakings
320,709
711,566

Other debtors
32,778
38,763

Prepayments and accrued income
3,956,145
3,222,633

Tax recoverable
-
86,191

5,985,093
4,801,921



18.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
3,999,940
1,333,917



19.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
2,403,919
1,545,177

Amounts owed to group undertakings
1,042,085
1,082,273

Other taxation and social security
437,072
431,106

Corporation tax
840,455
-

Other creditors
129,657
218,408

Accruals and deferred income
7,896,982
3,270,795

Other loans
3,863,699
-

16,613,869
6,547,759


Page 26

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

20.


Creditors: Amounts falling due after more than one year

2025
2024
£
£

Other loans
-
3,863,699

Amounts owed to group undertakings
2,052,694
2,052,694

2,052,694
5,916,393


The aggregate amount of liabilities repayable wholly or in part more than five years after the reporting date is:

2025
2024
£
£


Repayable by instalments
2,052,694
2,052,694

The amounts owed to group undertakings relates to a formal intercompany loan. The loan is repayable in full no later than 10 July 2030. Interest is accruing on the principal balance of 12% per annum.


21.


Loans


Analysis of the maturity of loans is given below:


2025
2024
£
£

Amounts falling due within one year

Other loans

3,863,699
-


Amounts falling due 2-5 years

Other loans

-
3,863,699



The other loans balance relates to unsecured loan notes issued. These are repayable by 30 January 2026 with an effective interest rate of 8.64% per annum. 

Page 27

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

22.


Deferred taxation




2025


£






At beginning of year
(419,515)


Charged to profit or loss
(127,724)



At end of year
(547,239)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Fixed asset timing differences
(778,284)
(657,476)

Short term timing differences
231,045
237,961

(547,239)
(419,515)


23.


Provisions




Other provision

£





At 1 January 2025
-


Charged to the profit or loss
103,068



At 31 December 2025
103,068

The other provision balance relates to a potential future VAT liability. The balance is estimated to be due in more than 1 year but not more than 5 years.


24.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



22,858 (2024 - 22,858) Ordinary shares of £0.01 each
229
229


Page 28

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

25.


Reserves

Share premium account

The share premium account represents the amount paid in excess of the nominal value for equity share capital.

Profit and loss account

The profit and loss account represents cumulative profits and losses net of other adjustments.


26.


Capital commitments


At 31 December 2025 the Company had capital commitments as follows:

2025
2024
£
£


Contracted for but not provided in these financial statements
36,334
485,819


27.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £200,669 (2024 - £157,215). Contributions totalling £46,501 (2024 - £74,166) were payable to the fund at the reporting date and are included in creditors.


28.


Commitments under operating leases

At 31 December 2025 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2025
2024
£
£


Not later than 1 year
675,570
654,021

Later than 1 year and not later than 5 years
1,511,213
2,169,490

2,186,783
2,823,511

Page 29

 
SYMPROVE LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

29.


Related party transactions

The company has taken advantage of the exemption conferred by Financial Reporting Standard 102 not to disclose transactions with members of the group headed by BD-C Feeling Midco Limited on the grounds that 100% of the voting rights in the company are controlled within that group.
Key management personnel are considered to be the directors. The total remuneration during the year to key management personnel is disclosed in note 9 of the accounts.


30.


Post balance sheet events

On the 22nd January 2026, 100% of the group's parent company’s share capital was acquired by Metagenics UK Ltd. 


31.


Controlling party

The immediate parent company of Symprove Ltd is Symprove Holdings Limited, whose registered office is Sandy Farm, The Sands, Farnham, Surrey, GU10 1PX.
The parent undertaking of the largest group, which includes Symprove Ltd and for which group accounts are prepared is BD-C Feeling Midco Limited, a company incorporated in England & Wales. Copies of the group financial statements of BD-C Feeling Midco Limited are available from Companies House, Crown Way, Cardiff, CF14 3UZ.
As at the balance sheet date the ultimate controlling party was BD Capital Partners Management (Guernsey) Limited, whose registered office is North Suite 2, Town Mills, Rue du Pre, St Peter Port, Guernsey, GY1 1LT . After the balance sheet date on the 22 January 2026 this changed to Gryphon Partners VI-A, LP and Gryphon Partners VI, LP, with no individual in overall control.  The registered office is The Corporation Trust Company, Corporation Trust Center 1209 Orange Street, Wilmington, DE 19801.  This change did not affect the company's operations or financial position as at the reporting date.

 
Page 30